Incremental value of strain rate imaging to wall motion analysis for prediction of outcome in patients undergoing dobutamine stress echocardiography.
BACKGROUND
Wall motion score at dobutamine stress echocardiography is an independent predictor of mortality. We sought to determine whether quantification of DSE by strain rate imaging was incremental to wall motion score for predicting outcome.


RESULTS
In 646 patients undergoing dobutamine stress echocardiography for the evaluation of known or suspected coronary disease, customized software was used to automatically measure peak systolic strain rate (SR(s)) and end-systolic strain (S(es)) in 18 segments. Results were expressed as the number of abnormal segments and the mean SR(s) and S(es) per patient. All-cause mortality was identified over 7 years of follow-up (mean, 5.2+/-1.5 years). Contributions of clinical, wall motion, and SR(s) and S(es) data to outcome were analyzed with Cox models, which also were used to define cut points for SR(s) and S(es). Ischemia (new or worsening wall motion abnormalities) was detected in 45%, and 39% had a previous myocardial infarction. In patients with no ischemia, annualized mortality without and with previous myocardial infarction were 2% and 3% compared with 5% in patients with ischemia. Peak wall motion score index, mean SR(s), segmental S(es), and segmental SR(s) were all predictors of mortality, but only segmental SR(s) (hazard ratio, 3.6; 95% CI, 1.7 to 7.2) was independently predictive. In sequential Cox models, the model based on clinical data (overall chi2, 12.7) was improved by peak wall motion score index (18.4, P=0.002) and further increased by either segmental SR(s) (31.8, P<0.001) or mean SR(s) (25.7, P=0.009).


CONCLUSIONS
Segmental analysis by SR(s), derived from automated strain rate imaging analysis of dobutamine stress echocardiography response, offers prognostic information that is independent and incremental to standard wall motion score index.
Bjork Ingul
Charlotte
C
University of Queensland, Brisbane, Australia.
Rozis
Ellen
E
Slordahl
Stig A
SA
Marwick
Thomas H
TH
D001285:Atropine; D001315:Australia / Q000453:epidemiology; D001794:Blood Pressure / Q000187:drug effects; D002316:Cardiotonic Agents; D003327:Coronary Disease / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000401:mortality; D004280:Dobutamine; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009038:Motion; D018727:Muscarinic Antagonists; D009200:Myocardial Contraction / Q000187:drug effects*; D011237:Predictive Value of Tests; D011379:Prognosis; D013314:Stress, Mechanical; D015996:Survival Rate; D013599:Systole
D002316:Cardiotonic Agents; D018727:Muscarinic Antagonists; D004280:Dobutamine; D001285:Atropine